

DAFTAR PUSTAKA

1. Moalem-Taylor G, Baharuddin B, Bennett B, Krishnan A V., Huynh W, Kiernan MC, et al. Immune dysregulation in patients with carpal tunnel syndrome. *Sci Rep* [Internet]. 2017;7(1):1–15. Available from: <http://dx.doi.org/10.1038/s41598-017-08123-6>
2. Ibrahim I, Khan W., Goddard N, Smitham P. Carpal Tunnel Syndrome: A Review of the Recent Literature. *Open Orthop J.* 2012;6(1):69–76.
3. Ghasemi-rad M. A handy review of carpal tunnel syndrome: From anatomy to diagnosis and treatment. *World J Radiol.* 2014;6(6):284.
4. Ricco M, Signorelli C. Personal and occupational risk factors for carpal tunnel syndrome in meat processing industry workers in northern Italy. *Med Pr.* 2017;68(2):199–209.
5. Nunez F, Vranceanu AM, Ring D. Determinants of pain in patients with carpal tunnel syndrome. *Clin Orthop Relat Res.* 2010;468(12):3328–32.
6. Luchetti R, Tognon S, Cacciavillani M, Ronco S. Observational multicentric survey on carpal tunnel syndrome: demographic and clinical data from 34 Italian centers. *Eur Rev Med Pharmacol Sci.* 2017;21:460–9.
7. Demiryurek, B.E and Gundogdu A. Prevalence of Carpal Tunnel Syndrome and Its Correlation With Pain. *Int J Occup Med Environ.* 2018;31(3):333–9.
8. Harris Z. Uji diagnostik Boston Carpal Tunnel questionnaire(BCTQ) versi Bahasa Indonesia sebagai instrumen untuk menentukan derajat keparahan Carpal tunnel Syndrome(CTS). Universitas Airlangga; 2017.
9. Storey PA, Fakis A, Hilliam R, Bradley MJ, Lindau T, Burke FD. Levine-Katz (Boston) Questionnaire analysis: Means, medians or grouped totals? *J Hand Surg Eur Vol.* 2009;34(6):810–912.
10. Öztürk N, Erin N, Tüzüner S. Changes in tissue substance P levels in patients with carpal tunnel syndrome. *Neurosurgery.* 2010;67(6):1655–60.
11. Fedorczyk JM, Barr AE, Rani S, Gao HG, Amin M, Amin S, et al. Exposure-dependent increases in IL-1 β , substance P, CTGF, and tendinosis in flexor digitorum tendons with upper extremity repetitive strain injury. *J Orthop Res.* 2010;28(3):298–307.
12. Ming Z, Zaproudina N, Siivola J, Nousiainen U, Pietikainen S. Sympathetic pathology evidenced by hand thermal anomalies in carpal tunnel syndrome. *Pathophysiology.* 2005;12(2):137–41.
13. Kotwal PP, Varshney MK. Carpal tunnel syndrome: Current concepts. *J Int Med Sci Acad.* 2011;24(1):21–5.
14. Sardana V, Ojha P. Carpal Tunnel Syndrome: Current Review. *Int J Med Res*

- Prof [Internet]. 2016;2(1):8–14. Available from: www.ijmrp.com
15. Zamborsky R, Kokavec M, Simko L, Bohac M. Carpal tunnel syndrome: Symptoms, causes and treatment options. A literature review. *Ortop Traumatol Rehabil*. 2017;19(1):1–8.
 16. De-La-Llave-Rincon AI, Ortega-Santiago R, Ambite-Quesada S, Gil-Crujera A, Puentedura EJ, Valenza MC, et al. Response of pain intensity to soft tissue mobilization and neurodynamic technique: A series of 18 patients with chronic carpal tunnel syndrome. *J Manipulative Physiol Ther* [Internet]. 2012;35(6):420–7. Available from: <http://dx.doi.org/10.1016/j.jmpt.2012.06.002>
 17. M.S A. Pathophysiology of carpal tunnel syndrome. *Carpal Tunn Syndr Relat Median Neuropathies Challenges Complicat*. 2015;20(1):4–9.
 18. Chammas M, Boretto J, Marquardt L, Matta R, Carlos F, Braga J. Carpal tunnel syndrome – Part I (anatomy , physiology , etiology and diagnosis) & , && [Internet]. Vol. 49, *Revista Brasileira de Ortopedia*. Sociedade Brasileira de Ortopedia e Traumatologia; 2014. 429–436 p. Available from: <http://dx.doi.org/10.1016/j.rboe.2014.08.001>
 19. Werner RA, Andary M. Carpal tunnel syndrome: Pathophysiology and clinical neurophysiology. *Clin Neurophysiol*. 2002;113(9):1373–81.
 20. Chang C, Jiang B, Chen C. Ion Channels Involved in Substance P-Mediated Nociception and Antinociception. 2019;1:1–13.
 21. Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and Their Receptors: Contributions to Physiological Control and the Mechanisms of Disease. *Physiol Rev* [Internet]. 2014;94(1):265–301. Available from: <http://www.physiology.org/doi/10.1152/physrev.00031.2013>
 22. Cohen SP, Mao J. Neuropathic pain: Mechanisms and their clinical implications. *BMJ*. 2014;348:1–12.
 23. Fong G, Backman LJ, Hart DA, Danielson P, McCormack B, Scott A. Substance P enhances collagen remodeling and MMP-3 expression by human tenocytes. *J Orthop Res*. 2013;31(1):91–8.
 24. Poernomo, H. BM dan WD. *Petunjuk Praktis Elektrodiagnostik*. Surabaya: Airlangga University Press; 2003.
 25. Sucher BM, Schreiber AL. Carpal tunnel syndrome diagnosis. *Phys Med Rehabil Clin N Am* [Internet]. 2014;25(2):229–47. Available from: <http://dx.doi.org/10.1016/j.pmr.2014.01.004>
 26. Kidd B. and UL. Mechanisms of Inflammatory Pain. *JCR J Clin Rheumatol*. 2004;10(Supplement):S5–11.
 27. Schank JR, Heilig M. Substance P and the Neurokinin-1 Receptor: The New CRF [Internet]. 1st ed. Vol. 136, *International Review of Neurobiology*. Elsevier

- Inc.; 2017. 151–175 p. Available from: <http://dx.doi.org/10.1016/bs.irn.2017.06.008>
28. Zieglgänsberger W. Substance P and pain chronicity. *Cell Tissue Res.* 2019;375(1):227–41.
 29. Mashaghi A, Marmalidou A, Tehrani M, Grace PM, Pothoulakis C, Dana R. Neuropeptide substance P and the immune response. *Cell Mol Life Sci.* 2016;73(22):4249–64.
 30. Zhou B, Zhou Y, Tang K. The effects of substance P on pluripotent tendon cells: An in vitro and in vivo study. *J Musculoskelet Neuronal Interact.* 2014;14(3):349–58.
 31. Lisowska B, Lisowski A, Siewruk K. Substance P and chronic pain in patients with chronic inflammation of connective tissue. *PLoS One.* 2015;10(10):1–9.
 32. Nowicki M, Ostalska-Nowicka D, Kondraciuk B, Miskowiak B. The significance of substance P in physiological and malignant haematopoiesis. *J Clin Pathol.* 2007;60(7):749–55.
 33. Snijdelaar D.G., Dirksen R SR et al. Substance P. *xPharm Compr Pharmacol Ref.* 2000;121–35.
 34. Li L, Liu X, Herr K. Postoperative pain intensity assessment: A comparison of four scales in Chinese adults. *Pain Med.* 2007;8(3):223–34.
 35. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and Molecular Mechanisms of Pain. *Cell.* 2009;139(2):267–84.
 36. Suvas S. Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis. *J Immunol [Internet].* 2017;199(5):1543–52. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28827386> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5657331>
 37. Sawamoto N, Honda M, Okada T, Hanakawa T, Kanda M, Fukuyama H, et al. Expectation of Pain Enhances Responses to Nonpainful Somatosensory Stimulation in the Anterior Cingulate Cortex and Parietal Operculum / Posterior Insula : an Event-Related Functional Magnetic Resonance Imaging Study. 2000;20(19):7438–45.
 38. Deleo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. 2001;90:1–6.
 - 39.Coderre TJ, Katz J, G ALV, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. 1993;52:259–85.
 40. Rainville P, Carrier B, Hofbauer RK, Bushnell MC, Duncan GH. Dissociation of sensory and affective dimensions of pain using hypnotic modulation. *Pain.* 1999;82(2):159–71.

41. Hulya Yucel. Factors affecting symptoms and functionality of patients with carpal tunnel syndrome: a retrospective study. *J PhysTher Sci* 271097-1101, 2015. 2015;
42. Greenslade JR, Mehta RL, Belward P, Warwick DJ. Dash and boston questionnaire assessment of carpal tunnel syndrome outcome: What is the responsiveness of an outcome questionnaire? *J Hand Surg Am.* 2004;29 B(2):159–64.
43. Komurcu HF, Kilic S, Anlar O. Relationship of age, body mass index, wrist and waist circumferences to carpal tunnel syndrome severity. *Neurol Med Chir (Tokyo).* 2014;54(5):395–400.
44. Malibary HM, Al-Najjar AT, Yassen DM, Abuhussain HAA, Radhwi OO, Alfares ZR. Clinical profile of carpal tunnel syndrome in a teaching hospital. *Pakistan J Med Sci.* 2013;29(1):2012–4.
45. Eslami S, Fadaei B, Baniasadi M, Yavari P. Clinical presentation of carpal tunnel syndrome with different severity: a cross sectional study. *Am J Clin Exp Immunol* [Internet]. 2019;8(4):32–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/31497381> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6726975>
46. Al Shahrani AS, Albogami SS, Alabdali AF, Alohalı SK, Almedbal HS, Aldossary GF. Does the use of electronic devices provoke the carpal tunnel syndrome (CTS) symptoms and functional impairment? A cross-sectional study. *Egypt Rheumatol* [Internet]. 2019;41(4):313–7. Available from: <https://doi.org/10.1016/j.ejr.2019.03.001>
47. A Cirakli., EK Ulusoy YE. The Role of Electrophysiological Examination in the Diagnosis of Carpal Tunnel Syndrome: Analysis of 2516 patients. 2018;731–4.
48. Kouyoumdjian JA. Carpal tunnel syndrome: Age, nerve conduction severity and duration of symptomatology. *Arq Neuropsiquiatr.* 1999;57(2 B):382–6.
49. Atwa ET, Esh AM, Abd El Al IT, Awad YM. Platelet-rich plasma versus corticosteroid injections for carpal tunnel syndrome: Clinical and electrophysiological study. *Egypt Rheumatol* [Internet]. 2019;41(3):237–41. Available from: <https://doi.org/10.1016/j.ejr.2018.07.008>
50. Padua L, Coraci D, Erra C, Pazzaglia C, Paolasso I, Loreti C, et al. Carpal tunnel syndrome: clinical features, diagnosis, and management. *Lancet Neurol* [Internet]. 2016;15(12):1273–84. Available from: [http://dx.doi.org/10.1016/S1474-4422\(16\)30231-9](http://dx.doi.org/10.1016/S1474-4422(16)30231-9)
51. Nageeb RS, Shehta N, Nageeb GS, Omran AA. Body mass index and vitamin D level in carpal tunnel syndrome patients. *Egypt J Neurol Psychiatry Neurosurg.* 2018;54(1):0–6.
52. Shiri R, Pourmemari MH, Falah-Hassani K, Viikari-Juntura E. The effect of

- excess body mass on the risk of carpal tunnel syndrome: A meta-analysis of 58 studies. *Obes Rev.* 2015;16(12):1094–104.
53. Guan W, Lao J, Gu Y, Zhao X, Rui J, Gao K. Case-control study on individual risk factors of carpal tunnel syndrome. *Exp Ther Med.* 2018;2761–6.